Pfizer Q4 Sales Lag Consensus; Forecasts $54B In FY22 From COVID-19 Vaccine, Treatment Pill


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Pfizer Inc (NYSE:PFE) has reported Q4 adjusted EPS of $1.08, well ahead of the consensus of $0.87, and more than doubled from $0.43 posted a year ago. 

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

  • The company achieved Q4 revenues of $23.84 billion, more than doubled, reflecting operational growth of $12.3 billion and an unfavorable impact of foreign exchange of $135 million, missing the Wall Street estimate of $24.20 billion.
  • Its COVID-19 vaccine, Comirnaty, contributed $12.5 billion in direct sales and alliance revenues in Q4, down from $13 billion in Q3 FY21.
  • Eliquis globally, up 19% operationally, driven primarily by continued increased adoption in non-valvular atrial fibrillation and oral anti-coagulant market share gains.
  • COVID-19 treatment Paxlovid contributed $76 million in U.S. sales after the FDA authorized it in late December 2021.
  • Prevnar sales declined 27% in the U.S. primarily due to disruptions to healthcare activity related to COVID-19, including the prioritization of primary and booster vaccination campaigns for COVID-19.
  • Chantix continues to be negatively impacted by the ongoing global pause in shipments.
  • FY22 Outlook: Pfizer expects FY22 sales of $98 billion - $102 billion, up 23% Y/Y at the midpoint.
  • The company expects adjusted EPS of $6.35 - $6.55.
  • Pfizer anticipates COVID-19 vaccine sales of $32 billion (lower than $36 billion expected in FY21) and around $22 billion in revenue for Paxlovid.
  • Price Action: PFE shares are trading 3.78% lower at $51.20 during the premarket session on the last check Tuesday.
  • Photo by x3 from Pixabay

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving